NCT02719171View on ClinicalTrials.gov

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

August 31, 2017

Conditions
Arthritis, Psoriatic
Interventions
DRUG

risankizumab

Risankizumab administered by SC injection

DRUG

placebo for risankizumab

Placebo for risankizumab administered by SC injection

Sponsors

Lead Sponsor

AbbVie

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

AbbVie

INDUSTRY